The healthcare and biotech sector delivered a mixed session, with a UK ePharmacy roll-up defending its margin discipline even as shares slid, while an established medical device maker confirmed guidance and launched a buyback. Elsewhere, a diagnostics minnow scored a European hospital win and a property-adjacent healthcare landlord cut its earnings outlook on tenant losses.
Vulcan Two grows margins through pharmacy acquisitions
Vulcan Two Group (LSE:VUL), which is assembling a regulated UK ePharmacy platform through acquisition, reported strong sales growth in general healthcare over the six months to 30 June, particularly in women's health and ADHD medications. The group, which acquired CloudRx, Hyperdrug and Webmed in a single move on 19 March, has since taken the harder step of pruning its own customer base, cutting a small number of lower-margin, higher credit-risk accounts, mostly weight-loss clinics, a decision it expects will dent near-term revenue but lift gross margin percentage. Shares fell 10.98% to 227.0p on the update.
The mechanics of the business are shifting in the company's favour: point-of-order payments now make up 85% of revenues, which supports cash conversion and caps bad-debt exposure. Cash balances stood at approximately £6.0 million at period end, though 2026 operating costs have risen on early hires and double-running expenses that management expects to unwind in 2027. Integration work is progressing on several fronts, fit-out of a 22,000 sq ft Leeds distribution facility remains on track for year-end completion, ERP systems are being unified, and Webmed's fulfilment is being folded into CloudRx. Keith Butcher has joined as chief financial officer, and a naming agency has been appointed to unify the group's brand under a single identity, with an announcement expected within weeks.
"We operate in a large, fragmented and fast-growing market with strong structural tailwinds," said Michael Kraftman, Chief Executive.
The market's negative reaction to a story built on margin improvement and disciplined execution says as much approximately investor appetite for near-term revenue sacrifice as it does approximately the underlying strategy. Cutting weight-loss clinic customers on credit-risk grounds is the kind of decision that looks better in twelve months than it does today, and the emphasis on cash conversion and reduced bad-debt exposure suggests management is deliberately trading growth optics for balance sheet quality. If the Leeds facility and ERP integration land on schedule, the double-running costs depressing 2026 profitability should fall away in 2027, leaving a cleaner platform, but the shares suggest the market wants to see that proof before it re-rates the story.
CLS Holdings cuts full-year EPS guidance
CLS Holdings plc, the office-focused property investor, warned that slower leasing activity and the departure of its largest tenant at Spring Gardens will weigh on earnings for the remainder of the year. The board now expects full-year EPRA earnings per share of 4.6 to 5.5p, well below current analyst consensus of 6.8p, with the shortfall concentrated in the second half.
Leasing transactions in the first half were steady but slower than anticipated, leaving vacancy broadly unchanged at 14.5%. The Group's largest tenant at Spring Gardens will not seek a short-term extension when its lease expires on 28 September, though the property has already been sold subject to planning, which limits further valuation damage at year-end. First-half EPRA earnings per share are expected at 2.7p, with EPRA net tangible assets of 177.7p per share as at 30 June, down mainly on a 4.6% fall in local-currency valuations driven by property yield expansion across all its markets.
The guidance cut confirms that office landlords remain exposed to structural leasing weakness even where individual assets have already found buyers, the Spring Gardens disposal caps the downside on that specific property, but it does nothing to fill the earnings hole left by the tenant's exit, and the wider vacancy rate shows the leasing market has not meaningfully tightened.
Convatec confirms guidance, launches $200 million buyback
Convatec Group (LSE:CTEC) reported organic revenue growth of 5.0% excluding InnovaMatrix for the six months to 30 June, down from 6.8% a year earlier, as the chronic care products maker confirmed it remains on track to meet full-year guidance. Shares rose 1.86% to 229.6p. Adjusted operating profit climbed 3.9% to $262 million, though reported operating profit fell 36.1% to $115 million after a $69 million non-cash impairment tied to InnovaMatrix, the skin substitute product hit by US Medicare reimbursement changes announced in October.
The InnovaMatrix damage is stark: revenue from the product has collapsed more than 90% after Medicare Administrative Contractors cut the reimbursement rate for skin substitute products by over 85%, and Convatec now expects just $5-10 million in full-year InnovaMatrix revenue, down from a prior estimate of roughly $20 million. Reported diluted earnings per share fell to 2.7 cents from 5.1 cents, while adjusted diluted EPS still rose 6.3% to 8.5 cents. "We are on track for another year of margin expansion and double-digit EPS growth," said Jonny Mason, Chief Executive.
The gap between reported and adjusted earnings tells the real story here, a single US reimbursement policy change has wiped out a product line almost entirely, yet the core chronic care business has absorbed the hit well enough to preserve double-digit adjusted EPS growth and justify a $200 million buyback. That resilience, rather than the InnovaMatrix writedown itself, is what the market rewarded.
Genedrive test adopted at leading Dutch hospital
genedrive (AIM:GDR), the point-of-care pharmacogenetic testing company, said its Genedrive MT-RNR1 ID Kit has been implemented at Erasmus MC University Medical Center in Rotterdam, effective from 3 August, sending shares up 15.0% to 1.15p. The test screens newborns for a genetic variant that puts them at risk of profound, irreversible hearing loss from aminoglycoside antibiotics, commonly used to treat suspected sepsis.
Erasmus MC's neonatal intensive care unit treats approximately 750 babies a year and is funding the rollout through its Pharmacogenetics International Expert Center, led by Professor Dr Ron H.N. van Schaik, head of the hospital's clinical chemistry department. "Aminoglycoside antibiotics remain an essential treatment for newborn babies with suspected sepsis, but a small number carry the MT-RNR1 genetic variant, placing them at risk of profound, irreversible hearing loss," van Schaik said, adding that rapid testing lets clinicians identify at-risk babies before treatment is given without delaying urgently needed antibiotics. Erasmus MC is the first Dutch medical centre to embed the technology into routine neonatal care.
A single NICU adoption is a modest revenue event on its own, but the credibility conferred by a leading Dutch academic hospital funding the rollout itself, rather than requiring genedrive to subsidise it, is the more valuable signal, reinforcing the company's pitch that international health systems are increasingly willing to pay for point-of-care pharmacogenetics rather than treat it as a research curiosity.
Eden Research wins Mevalone approvals in Slovakia and Egypt
Eden Research (EDEN) secured new regulatory approvals for its biopesticide Mevalone in Slovakia and Egypt, with shares edging up 1.96% to 2.6p. The Egyptian authorisation marks the product's first approval in North Africa, opening a new export-facing market for the company's plant protection technology.
"Egypt marks the first authorisation in North Africa for Mevalone and with no pre-harvest interval on the label, it provides a strong advantage for growers supplying highly regulated export markets," said chief executive Sean Smith. The absence of a pre-harvest interval requirement gives Mevalone a practical edge with growers who need to meet strict residue standards for produce destined for premium export markets.
